← Leaderboards
Jaume Padilla
Harry S. Truman Memorial Va Hospital
$7,120,291
Attributed
$11,428,928
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,428,928 · 7
VA$0 · 2
By mechanism
R01$10,442,803 · 5
K01$564,000 · 1
R21$422,125 · 1
I01$0 · 2
Top collaborators
- Luis A Martinez-Lemus12 shared
- Camila Margarita Manrique Acevedo6 shared
- Shawn Brady Bender1 shared
Most similar at Harry S. Truman Memorial Va Hospital
Same institution · by research overlap
- Camila Margarita Manrique Acevedo$5,456,962
- William P Fay$8,557,177
- Shiyou Chen$16,685,151
Others in their field
Top investigators on “Cardiovascular Diseases”
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$145,558,149
- Judith S. Currier · University Of California Los Angeles$143,001,230
- David M Nathan · Massachusetts Institute Of Technology$141,671,512
- John M Lachin · George Washington University$139,991,329
- Judith S Hochman · New York University School Of Medicine$112,514,057
Research focus
Cardiovascular DiseasesBlood VesselsMediatingDiabetes MellitusCardiovascular SystemNon-Insulin-Dependent Diabetes MellitusImpairmentBlood FlowArteriesLoss Of FunctionPreventExperimental StudyNitric OxideVasodilationPathogenesisPrevalenceClinical TrialsAnimal ModelEndotheliumEndothelial CellsExhibitsVasodilator AgentsInsulin ResistanceBlood Glucose Regulation
Grant awards (27)
Tissue transglutaminase as a therapeutic target for arterial stiffening and hypertension in obesity$685,654
R01 · FY2025 · HL
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2025 · HL
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$591,486
R01 · FY2025 · AG
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans with Obesity$0
I01 · FY2025 · VA · contact PI
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$667,915
R01 · FY2024 · HL
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$646,166
R01 · FY2024 · HL
SGLT2 inhibition as a therapeutic strategy to reverse arterial stiffening in aging$617,681
R01 · FY2024 · AG
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2024 · VA
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2023 · HL
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$679,698
R01 · FY2023 · HL
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2023 · VA
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$681,547
R01 · FY2022 · HL
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$679,698
R01 · FY2022 · HL
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes$0
I01 · FY2022 · VA
Role of neuraminidase activity on endothelial dysfunction in type 2 diabetes$693,303
R01 · FY2021 · HL
Targeting ADAM17 activity for correction of vascular insulin resistance in type 2 diabetes$679,426
R01 · FY2021 · HL
Restoring vasodilator actions of insulin in patients with type 2 diabetes$491,427
R01 · FY2021 · HL · contact PI
Restoring vasodilator actions of insulin in patients with type 2 diabetes$491,427
R01 · FY2020 · HL · contact PI
Restoring vasodilator actions of insulin in patients with type 2 diabetes$491,427
R01 · FY2019 · HL · contact PI
Restoring vasodilator actions of insulin in patients with type 2 diabetes$491,427
R01 · FY2018 · HL · contact PI
Vascular Insulin Resistance in Obesity: Role of Endoplasmic Reticulum Stress$141,000
K01 · FY2018 · HL · contact PI
Restoring vasodilator actions of insulin in patients with type 2 diabetes$491,427
R01 · FY2017 · HL · contact PI
Vascular Insulin Resistance in Obesity: Role of Endoplasmic Reticulum Stress$141,000
K01 · FY2017 · HL · contact PI
Targeting endoplasmic reticulum stress to correct vascular insulin resistance and glycemic dysregulation in diabetes$191,875
R21 · FY2016 · DK · contact PI
Vascular Insulin Resistance in Obesity: Role of Endoplasmic Reticulum Stress$141,000
K01 · FY2016 · HL · contact PI
Targeting endoplasmic reticulum stress to correct vascular insulin resistance and glycemic dysregulation in diabetes$230,250
R21 · FY2015 · DK · contact PI
Vascular Insulin Resistance in Obesity: Role of Endoplasmic Reticulum Stress$141,000
K01 · FY2015 · HL · contact PI